<DOC>
	<DOCNO>NCT00401635</DOCNO>
	<brief_summary>The purpose study evaluate activity toxicity combination carboplatin liposomal doxorubicin first-line chemotherapy patient advance recurrent endometrial carcinoma .</brief_summary>
	<brief_title>END-1 : First Line Chemotherapy Advanced Recurrent Endometrial Carcinoma With Carboplatin Liposomal Doxorubicin</brief_title>
	<detailed_description>Treatment plan carboplatin AUC 5 give IV day 1 liposomal doxorubicin 40 mg/m2 give IV day 1 , treatment repeat every 28 day . Delays treatment administration dose reduction plan accord toxicity .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Cytologic / histologic diagnosis endometrial carcinoma Indication chemotherapy Age 75 year less Life expectancy least 3 month Measurable disease &gt; 1 cm Previous concomitant malignant neoplasia ( include basocellular spinocellular skin carcinoma insitu carcinoma uterine cervix , provide adequately treat ) Performance status ( ECOG ) &gt; 2 Previous chemotherapy treatment Heart disease ( heart failure , myocardial heart attack within 6 month prior randomization , atrioventricular block degree , serious arrhythmia ) Leukocytes &lt; 4000/mm3 , platelet &lt; 100000/mm3 Impaired renal function ( creatinine &gt; = 1.25 time upper normal limit ) liver function ( SGOT SGPT &gt; = 1.25 time upper normal limit ) Present suspect hemorrhagic syndrome Uncooperative and/or unreliable patient Patient 's inability access center Refusal inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>advanced</keyword>
	<keyword>recurrent</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>first-line</keyword>
</DOC>